Edition:
India

Cumberland Pharmaceuticals Inc (CPIX.OQ)

CPIX.OQ on NASDAQ Stock Exchange Global Select Market

7.89USD
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
$7.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,310
52-wk High
$7.95
52-wk Low
$5.30

Summary

Name Age Since Current Position

A. Kazimi

56 2016 Chairman of the Board, Principal Executive Officer

Michael Bonner

2016 Senior Director Finance and Accounting and Chief Financial Officer

Martin Cearnal

70 2008 Senior Vice President, Chief Commercial Officer, Director

Leo Pavliv

55 2012 Senior Vice President - Operations, Chief Development Officer

James Herman

59 2011 Vice President - National Accounts, Chief Compliance Officer

Amy Rock

2016 Vice President - Regulatory & Scientific Affairs

Gordon Bernard

62 2010 Independent Director

Jonathan Griggs

80 2010 Independent Director

Joey Jacobs

62 2011 Independent Director

James Jones

68 2010 Independent Director

Kenneth Krogulski

60 2017 Independent Director

Thomas Lawrence

75 1999 Independent Director

Caroline Young

2016 Independent Director

Biographies

Name Description

A. Kazimi

Mr. A. J. Kazimi is Chairman of the Board, Principal Executive Officer of the Company. He was Principal Financial Officer of Cumberland Pharmaceuticals Inc. He founded the company in 1999. His career includes 25 years in the biopharmaceutical industry. Prior to joining the company, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company’s growth from its start-up phase through its initial public offering and product launches. Mr. Kazimi oversaw operations in three countries and was personally involved with the company’s product development strategies, approvals, licensing agreements and the raising of over $100 million in equity and debt financings. Prior to that role, Mr. Kazimi worked at Brown-Forman Corporation, rising through a series of management positions and helping to launch several new products. Mr. Kazimi previously served on the board of directors for Aegis Toxicology Sciences Corporation, a federally certified forensic toxicology laboratory. He currently serves as a director of the Nashville Health Care Council, an industry association representing the concentration of healthcare companies in the United States. He also serves as Chairman and Chief Executive Officer of Cumberland Emerging Technologies, Inc (CET). He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt University Owen Graduate School of Management.

Michael Bonner

Mr. Michael Bonner is Senior Director Finance and Accounting and Chief Financial Officer of Cumberland Pharmaceuticals Inc. Mr. Bonner has 16 years of finance and accounting experience, primarily within the health care industry. Prior to joining Cumberland, his most recent position was at Advocat Inc. a $300 million NASDAQ listed health care provider, as Vice President of Accounting and Financial Reporting. Prior to that, he had similar responsibilities at LifePoint Hospitals, a NASDAQ listed health care provider. Mr. Bonner started his career in the assurance practice at Ernst & Young. A Certified Public Accountant, Mr. Bonner has a Bachelor of Science in accounting and business administration and his MBA with an emphasis in accounting.

Martin Cearnal

Mr. Martin E. Cearnal is Senior Vice President, Chief Commercial Officer and Director of Cumberland Pharmaceuticals Inc. In 2008, he joined our management team to head commercial development for Cumberland, currently serving as Senior Vice President and Chief Commercial Officer. He is the former President and Chief Executive Officer of Physicians World, which became the largest provider of continuing medical education during his tenure from 1985 to 2000. Physicians World was acquired by Thomson Healthcare in 2000, and Mr. Cearnal served as President of Thomson Physicians World from 2000 to 2003 and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. He then became Executive Vice President-Chief Strategy Officer for Jobson Medical Information. Mr. Cearnal has 45 years of experience in the healthcare industry and has been involved with the launches of such noteworthy pharmaceutical products as Lipitor®, Actos®, Intron-A®, Straterra®, Botox® and Humira®. He spent 17 years at Revlon Healthcare in a variety of domestic and international pharmaceutical marketing roles culminating in his position as Vice President, Marketing for International Operations. He has a B.S. degree from Southeast Missouri State University.

Leo Pavliv

Mr. Leo Pavliv, R. Ph., is Senior Vice President - Operations and Chief Development Officer of Cumberland Pharmaceuticals Inc. He is responsible for Cumberland’s overall drug development, including manufacturing and quality operations, and has over 26 years of experience developing pharmaceutical and biological products. From 1997 to 2003, he worked at Cato Research, a contract research organization, most recently as Vice President of Pharmaceutical Development where he oversaw development of a wide variety of products throughout the development cycle. Prior to 1997, he held various scientific and management positions at both large pharmaceutical and smaller biopharmaceutical firms including Parke-Davis from 1984 to 1986, Agouron Pharmaceuticals from 1992 to 1997, ProCyte from 1989 to 1992, and Interferon Sciences from 1986 to 1989. He is a registered pharmacist (R.Ph.) and is regulatory affairs certified. Mr. Pavliv holds a B.S., Pharmacy, and an M.B.A. from Rutgers University.

James Herman

Mr. James L. Herman is Vice President - National Accounts and Chief Compliance Officer of Cumberland Pharmaceuticals Inc. Mr. Herman handles all national accounts sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He is also charged with overseeing our corporate compliance efforts. He has been with us since 2003 and has 24 years of pharmaceutical industry experience. From 1998 to 2003, he was with Solvay Pharmaceuticals and served as Director of Managed Care and Director of Trade Affairs and Customer Service. From 1990 to 1998, Mr. Herman was with Schwarz Pharma, where he held national sales leadership positions in National Accounts and Managed Care. He holds a B.S. from Indiana University and an M.B.A. from Cardinal Stritch University.

Amy Rock

Dr. Amy Dix Rock, Ph.D., is Vice President - Regulatory & Scientific Affairs of Cumberland Pharmaceuticals Inc. She was Senior Director, Regulatory and Scientific Affairs. Dr. Rock joined the company in 2001 and built Regulatory Affairs Department and infrastructure. In addition to managing all interactions between the company and the FDA, Dr. Rock oversees the preparation of pre-approval and post-approval regulatory submissions. Her additional responsibilities include involvement in protocol development and clinical trials management, overseeing the medical call center and supporting the corporate compliance initiatives. She holds a B.A. from Washington University, a Ph.D. in Immunology from the University of Kentucky, and an M.B.A. from the Vanderbilt Owen Graduate School of Management.

Gordon Bernard

Dr. Gordon R. Bernard M.D. is an Independent Director of Cumberland Pharmaceuticals Inc. since 2010. Dr. Bernard is the Associate Vice-Chancellor for Research at Vanderbilt University, and also the Melinda Owen Bass Professor of Medicine and former Chief of the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt. In addition, he is Senior Associate Dean for Clinical Sciences and Chairman of Vanderbilt’s Pharmacy and Therapeutics Committee, which is responsible for approving the Vanderbilt Medical Center Formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980, and he has been steering committee chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994. This network is the only federally supported, ongoing system for the conduct of research in the hospital Intensive Care Unit, or ICU. He holds a B.S. from the University of Southwestern Louisiana and an M.D. from Louisiana State University. Dr. Bernard maintains an active practice as an Intensivist in the Medical ICU at Vanderbilt and is therefore in a position to observe, firsthand, the pharmaceutical management issues surrounding the care of a wide variety of the most severely ill patients and identify their unmet medical needs.

Jonathan Griggs

Mr. Jonathan Griggs is an Independent Director of Cumberland Pharmaceuticals Inc. since 2010. His career includes more than 40 years in the pharmaceutical and biotechnology industries that includes international experience. He spent 23 years at Warner Lambert Corporation in positions of increasing responsibility becoming its Vice President of Human Resources. During his tenure with Warner Lambert, he provided leadership for the integration of three pharmaceutical businesses into what became Parke Davis, the consolidation in the industry at that time. From 1992 to present, he has been the CEO of Griggs & Associates, a management and human resources consulting firm assisting startup companies and providing critical assistance in turnaround situations. Mr. Griggs also provided the leadership and strategic management for the formation and establishment of the AACA (Antique Auto Club of America) Museum, a transportation museum where he served as chairman and is currently a director. Mr. Griggs has his B.S. Degree from Penn State and attended the Wharton School of Management at the University of Pennsylvania. He was an advisor to Cumberland as a member of the Company’s Pharmaceutical Advisory Board from the Company’s inception in 1999 until he was appointed to the Board in 2010. The Board believes Mr. Griggs’ experience in strategic management and human resources consulting will be critical as the Company continues to build a strong, effective management team.

Joey Jacobs

Mr. Joey A. Jacobs is Independent Director of Cumberland Pharmaceuticals Inc. since January 1, 2011. He is a healthcare veteran with more than 35 years of industry experience, Mr. Jacobs is currently the Chairman and Chief Executive Officer of Acadia Healthcare Company Inc., a behavioral health company traded on the Nasdaq Global Market. Mr. Jacobs is the former Chairman, President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. (PSI), which he co-founded in 1997 and grew into a $2 billion behavioral healthcare system before the company’s sale to Universal Health Services in 2010. Prior to founding PSI, Mr. Jacobs spent 21 years at Hospital Corporation of America, or HCA, where he served in various capacities, including President of HCA’s Tennessee Division. Mr. Jacobs’ background at HCA also includes serving as President of HCA’s Central Group, Vice President of the Western Group, Assistant Vice President of the Central Group and Assistant Vice President of the Salt Lake City Division. In addition to serving as the former Chairman of the Nashville Health Care Council, he is also the past director of the Federation of American Hospitals and the National Association of Psychiatric Health Systems. He is currently a board member of the Monroe Carell, Jr. Children’s Hospital at Vanderbilt and Mental Health Management. Mr. Jacobs holds a B.S. degree from Middle Tennessee State University.

James Jones

Mr. James R. Jones is Independent Director of Cumberland Pharmaceuticals Inc. Mr. Jones’ 35 year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. He served in various capacities during his career at KPMG which also included positions at their offices in Jackson, Mississippi, Washington, DC and Greenville, South Carolina. During his tenure with KPMG, Mr. Jones led a team of more than 100 individuals providing accounting services for an client base. Following retirement in 2006, he has served as an advisor and provided various consulting services to several companies, including acting as liaison between management and the board of directors of a long-term care facility and serving as interim CEO of a charitable organization. He is currently a board director and member of the audit committee of Argent Trust Company of Tennessee. Mr. Jones holds a B.S. from Mississippi College and an M.B.A. from Mississippi State University.

Kenneth Krogulski

Mr. Kenneth J. Krogulski, CFA has been appointed as Independent Director of the Company effective January 18, 2017. Mr. Krogulski has over 37 years' experience in security analysis and portfolio management. He began his career in finance at First Eastern Bank (now PNC Financial) as an investment analysis and portfolio manager. He then served as senior portfolio manager in First Easter's Trust department. Mr. Krogulski then joined Berkshire and later led a management buy-out acquiring the company from Legg Mason. Under his leadership, Berkshire's assets under supervision have grown from$600 million in 2006 and are now over$1.5 billion. He earned his B.S. in finance from Indiana University of Pennsylvania and his M.B.A from Wilkes University. He holds the Chartered Financial Analysts designation.

Thomas Lawrence

Mr. Thomas R. Lawrence is Independent Director of Cumberland Pharmaceuticals Inc. Since 2003 he has been Chairman of Aetos Technologies Inc., a corporation formed in 2003 by Auburn University to market technological breakthroughs by its faculty. Since 1998, Mr. Lawrence advises business clients on matters of marketing and corporate governance through his firm Capital Consultants. He previously served as Co-Founder and Managing Partner of Delta Capital Partners, or Delta, in Memphis from 1989 to 1998. The partnership made investments in ten early-stage companies which, by 1998, were valued at more than $30 million. Prior to the formation of Delta, Mr. Lawrence founded several companies in the areas of commercial leasing and venture capital financing. He also worked for most of the 1980s as an Institutional Sales Representative and Commercial Leasing Specialist with the Investment Banking Group of Union Planters Bank in Memphis, where he was responsible for the structure and sale of over $1 billion in securities. He holds a B.A. from Mississippi State University.

Caroline Young

Ms. Caroline Young has been appointed as Independent Director of the Company, effective September 13, 2016. Caroline is the prior President of the Nashville Health Care Council and founding Executive Director of the Tennessee Biotechnology Association. Caroline was the President of the Nashville Health Care Council from 2008 to 2015. The Council was formed as an association of the largest concentration of healthcare companies in the U.S., which are headquartered in the Nashville area. It is one of the nation’s foremost health care industry associations, and under Caroline’s leadership, membership grew to encompass 300 diverse organizations. There, she oversaw a series of international trade missions and launched one-of-a-kind Health Care Council Fellows program, designed to encompass the healthcare perspective and further develop the skills of senior business executives. Additionally, she expanded the Council’s innovative Leadership Health Care program, dedicated to nurturing the talents of the next generation of health care industry leaders. Prior to the Council, Caroline was the founding Executive Director of Tennessee Biotechnology Association (now Life Science Tennessee) from 2002 to 2004. She also served in communications roles for the State of Tennessee’s Department of Economic and Community Development from 1998 to 2002.